Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pol J Microbiol ; 67(3): 259-272, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30451442

RESUMO

The growing resistance of microorganisms towards antibiotics has become a serious global problem. Therapeutics with novel chemical scaffolds and/or mechanisms of action are urgently needed to combat infections caused by multidrug resistant pathogens, including bacteria, fungi and viruses. Development of novel antimicrobial agents is still highly dependent on the discovery of new natural products. At present, most antimicrobial drugs used in medicine are of natural origin. Among the natural producers of bioactive substances, Actinobacteria continue to be an important source of novel secondary metabolites for drug application. In this review, the authors report on the bioactive antimicrobial secondary metabolites of Actinobacteria that were described between 2011 and April 2018. Special attention is paid to the chemical scaffolds, biological activities and origin of these novel antibacterial, antifungal and antiviral compounds. Arenimycin C, chromopeptide lactone RSP 01, kocurin, macrolactins A1 and B1, chaxamycin D as well as anthracimycin are regarded as the most effective compounds with antibacterial activity. In turn, the highest potency among selected antifungal compounds is exhibited by enduspeptide B, neomaclafungins A-I and kribelloside D, while ahmpatinin i Bu, antimycin A1a, and pentapeptide 4862F are recognized as the strongest antiviral agents.


Assuntos
Actinobacteria/metabolismo , Antibacterianos/química , Antifúngicos/química , Antivirais/química , Produtos Biológicos/química , Metabolismo Secundário , Antibacterianos/farmacologia , Antifúngicos/farmacologia , Antivirais/farmacologia , Bactérias/efeitos dos fármacos , Produtos Biológicos/farmacologia , Fungos/efeitos dos fármacos , Estrutura Molecular , Vírus/efeitos dos fármacos
2.
J Antibiot (Tokyo) ; 71(8): 757-761, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29700424

RESUMO

A new metabolite, cyclic dipeptide, cis-(3S,8aS)-3-(3,4-dihydroxybenzyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione, named JS-3 was isolated from Streptomyces sp. 8812 fermentation broth. Its chemical structure was established by means of spectroscopic analysis. A wide-range-screening study, which included inhibition assay of DD-carboxypeptidase/transpeptidase activity, determination of antibacterial, antifungal, and antiproliferative activities as well as free-radical scavenging was performed. To authors knowledge, this is the first isolation of such compound from natural sources and the first one from bacteria, Streptomyces.


Assuntos
Antibacterianos/farmacologia , Antifúngicos/farmacologia , Carboxipeptidases/antagonistas & inibidores , Dicetopiperazinas/farmacologia , Dipeptídeos/farmacologia , Peptidil Transferases/antagonistas & inibidores , Streptomyces/metabolismo , Antibacterianos/isolamento & purificação , Antifúngicos/isolamento & purificação , Bactérias/efeitos dos fármacos , Dicetopiperazinas/isolamento & purificação , Dicetopiperazinas/metabolismo , Dipeptídeos/isolamento & purificação , Dipeptídeos/metabolismo , Fermentação , Fungos/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...